SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla recalling 4,800 bottles of Nevirapine extended release tablets from US

31 Dec 2018 Evaluate

Cipla is recalling 4,800 bottles of Nevirapine extended release tablets used for the treatment of human immunodeficiency virus (HIV) from the American market. The main reason for recalling of the bottles is due to failed dissolution specifications. Nevirapine extended release tablets, 400 mg in the 30-count bottle have been manufactured by Cipla at its Goa facility for Cipla USA Inc.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1334.85 24.95 (1.90%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×